Gene therapy of lymphoma

被引:10
作者
Buttgereit, P [1 ]
Schmidt-Wolf, IGH [1 ]
机构
[1] Univ Bonn, Med Klin & Poliklin 1, D-53105 Bonn, Germany
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2002年 / 11卷 / 03期
关键词
D O I
10.1089/15258160260090924
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gene therapy offers new and promising treatment for patients with hematological malignancies. Tumor cells-lymphoma cells, for example-are possible targets for gene therapy. In general, gene therapeutic approaches require efficient gene transfer into host cells and sufficient transgene expression. Although many methods of gene transfer into mammalian cells exist, most do not allow efficient DNA transfer into primary lymphocytes. In contrast to gene transfer into tumor cells and many other cell types, which can be successfully performed using a variety of methods, the efficient expression of foreign DNA in lymphoma cells presents unique problems and challenges, requiring a careful selection of the mode of gene transfer. In this review, we discuss the current strategies for gene therapy in the treatment of lymphoma. We also summarize the current gene transfer methods for lymphoma cells and efficiency of transgene expression.
引用
收藏
页码:457 / 467
页数:11
相关论文
共 94 条
[1]   Hybrid female matings are directly related to the availability of Rana lessonae and Rana esculenta males in experimental populations [J].
Bergen, K ;
Semlitsch, RD ;
Reyer, HU .
COPEIA, 1997, (02) :275-283
[2]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[3]   Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome [J].
Bishop, MR ;
Jackson, JD ;
Tarantolo, SR ;
OKaneMurphy, B ;
Iversen, PL ;
Bayever, E ;
Joshi, SM ;
Sharp, JG ;
Pierson, JL ;
Warkentin, PI ;
Armitage, JO ;
Kessinger, A .
JOURNAL OF HEMATOTHERAPY, 1997, 6 (05) :441-446
[4]  
Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO
[5]  
2-6
[6]   Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach [J].
Brand, K ;
Loser, P ;
Arnold, W ;
Bartels, T ;
Strauss, M .
GENE THERAPY, 1998, 5 (10) :1363-1371
[7]  
Brenner MK, 1996, CYTOKINES MOL THER, V2, P193
[8]  
Brenner MK, 1996, GENE THER, V3, P278
[9]   Gene and cell transfer for specific immunotherapy [J].
Brenner, MK ;
Heslop, HE ;
Rooney, CM .
VOX SANGUINIS, 1998, 74 :87-90
[10]   Improving stable transfection efficiency:: antioxidants dramatically improve the outgrowth of clones under dominant marker selection [J].
Brielmeier, M ;
Béchet, JM ;
Falk, MH ;
Pawlita, M ;
Polack, A ;
Bornkamm, GW .
NUCLEIC ACIDS RESEARCH, 1998, 26 (09) :2082-2085